18 October, 2022
Authored and Edited by Jamie Barcombe; K. Victoria Barker, Ph.D.; Maeve O'Flynn
The question of priority rights in Europe focuses on the applicant who was named on the priority application and the applicant who was named when the priority-claiming application (such as a PCT application) was filed. In Europe, it is all about the applicant, and - as the Broad Institute learned the hard way (see the so-called “CRISPR decision”) - the consequences of getting this wrong can be catastrophic. The requirements for a valid priority claim are now under further scrutiny at the EPO, with two new questions having been referred to the Enlarged Board of Appeal in G 1/22 and G 2/22.
The first question referred to the Enlarged Board asks whether the EPC confers jurisdiction on the EPO to determine whether a party validly claims to be a successor in title as referred to in Article 87(1)(b) EPC. The alternative would be that national law, such as the law in the applicant’s country, applies.
In the past, the Technical Boards of Appeal seem to have considered the answer to this question to be that the EPO does have jurisdiction, but this question has not previously been referred to the Enlarged Board of Appeal.
Since we can assume based on past EPO practice that the answer to the first question will be “yes”, the Enlarged Board will move on to consider the second referred question concerning joint applicants.
For a priority claim to be valid at the EPO, all applicants from the priority application, or their successors in title, must be listed as applicants for the European application. It is accepted case law that the priority claim for a European patent is valid for all designated European Contracting States, providing all priority applicants (or their successors in title) are listed as applicants on the European application for at least one EPC Contracting State. This is often referred to as the “joint applicants approach”.
The second question referred to the Enlarged Board asks whether a joint applicants approach should also apply to PCT applications. In each of the cases resulting in the pending appeals (T 1513/17 and T 2719/19), the applicants for the priority application are listed as applicants only for the US designation of the PCT application in question, whilst different applicants not entitled to claim priority are listed as applicants for all other designations, including the European phase. Therefore, the referrals ask whether the presence of the priority applicants on the PCT application for the US designation only results in a valid priority claim for all designations.
The Enlarged Board of Appeal has not yet set a date for oral proceedings, but these are expected to take place in 2023. We will continue to monitor the referrals and provide an update in due course.
For more information on priority, read our guide to priority in the UK here.
Copyright © 2022 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.